Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO

IPO-Pricing

Drugs Made in America Acquisition Corp. (DMAAU) Prices $200M IPO


Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DMAAU”, Tuesday, January 28, 2025.

The new SPAC intends to combined with a target company in the pharmaceutical industry that has products derived from plant-based raw materials.

Drugs Made in America’s sponsor team is led by Chief Executive Officer and Executive Chair Lynn Stockwell, and Chief Financial Officer Glenn Worman. Catherine Do, Sridhar Prasad and Myron W. Shulgan will serve on its Board of Directors.

Total SPAC deal count for 2025 year-to-date is now 6. This offering is expected to close on Wednesday, January 29, 2025.


Clear Street is acting as the sole book-running manager in the offering. Loeb & Loeb LLP is serving as Issuer’s Counsel with Winston & Strawn LLP serving as Underwriter’s Counsel. MaloneBailey LLP serves as auditor. Wilmington Trust, National Association is acting as trustee.